DailyIQ
Last updated1 minute ago

ZBH·Zimmer Biomet Holdings, Inc.

$91.31
-0.77 (-0.84%)
High
$92.61
Open
$92.20
Market Cap
17.84B
52W High
$106.88
Low
$90.65
P. Close
$91.31
P/E
22.13
52W Low
$79.12
Fwd P/E
10.09
DailyIQ Est.
$107.11
Inst. Ownership
40.6%
Short Interest
5.03%
Days to Cover
4.4
Div. Yield
1.04%
Next Ex-Div
~Dec 30
Technical Score (1D)
31
BEARISH
News Sentiment
71
BULLISH
On Oct 13, Zimmer Biomet announced that it had extended its distribution agreement with THINK Surgical for the company’s knee surgery robot, keeping the partnership in place for an additional period and allowing Zimmer Biomet surgeons continued access to the robotic platform. The same day, the company also disclosed a multi‑year extension of its Limited Exclusive Distribution and Supply Agreement with THINK Surgical, securing exclusive distribution of the TMINI Miniature Robotic System, which is compatible with Zimmer Biomet’s Persona Knee System. The extensions were reported to support Zimmer Biomet’s strategy to broaden its robotic orthopedic offerings and maintain market presence in the knee surgery segment. They were also said to accelerate adoption of the TMINI platform across Zimmer Biomet’s orthopedic product line and reinforce the perceived value of the robotic system. Both sources highlighted that the deals strengthen Zimmer Biomet’s position in the surgical robotics market.
LOW TARGET
$93 +1.9%
3 analysts
MEAN TARGET
$107 +17.0%
23 analysts
HIGH TARGET
$130 +42.4%
9 analysts
PRICE RANGE
$93.00 - $130.00
SB / B / H / S / SS
3/8/22/1/1
DAILYIQ EST.
$107.11 (+17.3%)
Sector
Healthcare
Industry
Medical Devices
Exchange
NYQ
Country
United States
Symbol
ZBH
Description
Zimmer Biomet Holdings is a global medical technology firm specializing in the design, production, and distribution of orthopedic and related medical devices. The company's core business revolves around providing solutions for musculoskeletal health, encompassing reconstructive products for knees and hips, as well as specialized offerings for sports medicine, trauma, and craniomaxillofacial applications. Zimmer Biomet's products are utilized by surgeons and healthcare providers to address a range of conditions affecting bones, joints, and soft tissues. This established firm, founded in 1927, also develops surgical robotics to enhance precision in implant placement, solidifying its position within the competitive medical device landscape.
Bought (1Y)
0 shares
$0
Sold (1Y)
19,369 shares
$1.8M
Campbell Gary CraigPresident, Americas
Option Exercise1,218 shares2026-10-01
Campbell Gary CraigPresident, Americas
Option Exercise2,368 shares2026-10-01
Campbell Gary CraigPresident, Americas
Tax Withholding480 shares2026-10-01
Campbell Gary CraigPresident, Americas
Option Exercise1,218 shares2026-10-01
Campbell Gary CraigPresident, Americas
Tax Withholding932 shares2026-10-01
72/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
69.7%
Net Margin
8.6%
Revenue CAGR
4.2%
Current Ratio
1.98x
Debt / Equity
0.59x
Return on Equity
5.6%
Earnings Summary
Zimmer Biomet Holdings is a leading medical‑device manufacturer focused on orthopedic and related products, including knee and hip implants and surgical robotics, operating within the healthcare medical‑devices industry. In Q4 2025, the company posted revenue of $2.2438B, up from $2.0733B in Q4 2024, and EPS of $2.42 versus $2.31, beating estimates; Q2 2026 revenue rose to $2.177B from $2.077B in Q2 2025, with EPS of $2.07 versus $2.07, matching the $2.03 estimate, indicating a stable earnings performance. Across the last four quarters, Zimmer Biomet has consistently exceeded EPS estimates, with revenue growth averaging 4-5% quarter‑over‑quarter, while maintaining a YoY revenue increase of about 8% in 2025. The company’s historical streak shows a pattern of solid earnings beats and steady revenue expansion, even as it navigates competitive pressures in the orthopedic market. Recent developments include the extension of distribution agreements with THINK Surgical for its knee surgery robot and the TMINI Miniature Robotic System, reinforcing the company’s robotic orthopedic portfolio; a downgrade of the price target by Leerink Partners reflects some analyst concern over competitive dynamics.

EPS

EstBeatMiss
$1.67$1.88$2.09$2.31$2.52Q1'25Q2'25Q3'25Q4'25Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.88 - -
Q2'26$2.03$2.07+2.0%
Q4'25$1.91$2.42+26.8%
Q3'25$1.87$1.90+1.8%
Q2'25$1.98$2.07+4.8%
Q1'25$1.77$1.81+2.3%

Revenue

EstBeatMiss
$1.9B$2.0B$2.1B$2.2B$2.3BQ1'25Q2'25Q3'25Q4'25Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.1B - -
Q2'26$2.2B$2.2B+1.0%
Q4'25$2.1B$2.2B+9.0%
Q3'25 - $2.0B -
Q2'25 - $2.1B -
Q1'25 - $1.9B -

Market Data

ZBH Stock Snapshot

BEARISH31/100
$91.31−$0.77 (0.8%)
Market cap
17.84B
P/E ratio
22.1
Day range
$90.65 – $92.61
News sentiment
71/100 · Bullish
Analyst target
$106.82 (+17.0%)
Consensus
Hold · 35 analysts
52-week range+15.4% off low · -14.6% from high
$79.12$106.88
Price $91.31 DailyIQ Est. $107.11

The signals on ZBH lean bearish, and the range position backs that up. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Reverse DCF

What growth is priced into ZBH?

CHEAP

At today's price, Zimmer Biomet Holdings, Inc. needs to grow free cash flow about -3.7% a year for the next 10 years to justify its valuation at a 7.10% cost of capital. Over its actual history it has compounded free cash flow at 2.7% a year, so the market is asking for 6.4 percentage points below its own delivered rate. On that basis ZBH looks priced below what its own growth record supports.

Implied FCF growth
-3.7%
Historical FCF CAGR
2.7%
Growth gap
-6.4 pts
Verdict
CHEAP
Discount rate (WACC)
7.10%
Beta
0.49

Behaviour On Record

What ZBH's own history says about today's numbers

Realized volatility (21d)
30.2% 80th pct
Below its peak
-46.9%
vs 200-day average
+0.8%
Up days (1y)
53%

Zimmer Biomet Holdings, Inc. is currently running 30.2% annualised volatility over the last 21 sessions. Measured against ZBH's own 13 years of daily returns rather than a market-wide average, that is the 80th percentile — elevated for this stock, against a typical reading of 22.3%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

ZBH is trading -46.9% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -24.1%, and the deepest was -49.7% in 2020. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +0.8% from its 200-day moving average. Against every other day in its history, that gap ranks at the 55th percentile — close to the gap it normally carries. Over the past year ZBH closed higher on 53% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 14 years of records, ZBH finished the month higher 8 of 14 times, with a median return of +1.5% and an average of -0.4%. Its strongest month historically has been July at +4.0% on average, its weakest September at -2.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: ZBH has opened more than 2% away from the prior close in 110 of 3,268 sessions (3.4% of the time), with the largest gaps running +8.7% and -9.9%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against ZBH's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of ZBH's sector?

Zimmer Biomet Holdings, Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Medical Devices industry group, ZBH ranks 3rd of 15 tracked industries, leading.

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
91
Industry rank
#3 of 15

Options Market

What is the options market pricing for ZBH?

CallsPuts

For Zimmer Biomet Holdings, Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.71), with at-the-money implied volatility around 45.8%. The options market is pricing roughly a ±3.1% move by that expiry — a range of about $88.24–$93.82.

Put/call ratio (2026-10-16)
0.71
ATM implied volatility
45.8%
Total open interest
1,676
Expected move by 2026-10-16
±3.1% ($88.24–$93.82)

Analyst Rating Changes

Are analysts turning bullish or bearish on ZBH?

Barclays most recently initiated coverage on Zimmer Biomet Holdings, Inc. to Equal-Weight on Oct 7, 2026 with a price target of $100. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Barclays — Equal-Weight
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 7, 2026BarclaysInitiatedEqual-Weight$100
Aug 10, 2026Canaccord GenuityMaintainedHold$83 → $100
Aug 7, 2026Truist SecuritiesMaintainedHold$92 → $106
Aug 6, 2026RBC CapitalMaintainedOutperform$101 → $110
Aug 6, 2026BernsteinMaintainedMarket Perform$91 → $93
Aug 6, 2026StifelMaintainedBuy$105 → $110
Jul 9, 2026BMO CapitalInitiatedOutperform → Market Perform$95
Jul 6, 2026Evercore ISI GroupMaintainedOutperform$120 → $110
May 28, 2026CitigroupMaintainedNeutral$95 → $93
Apr 29, 2026JP MorganMaintainedNeutral$100 → $95
Apr 29, 2026CitigroupMaintainedNeutral$98 → $95
Apr 29, 2026CitizensMaintainedMarket Outperform$120 → $105

Peers & ETF holders

ZBH peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

71/100
Strong NegativeNeutralStrong Positive
BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Zimmer Biomet announced on October 13 that it would extend its distribution agreement with THINK Surgical for the company's knee surgery robot. The extension keeps the partnership in place for an additional period, allowing continued access to THINK’s robotic platform for Zimmer Biomet’s surgeons. The move supports Zimmer Biomet’s strategy to broaden its robotic orthopedic offerings and maintain market presence in the knee surgery segment.
What did this article say?
On October 13, 2026, Zimmer Biomet Holdings (ZBH) announced a multi‑year extension of its exclusive distribution and supply agreement with THINK Surgical. The extension will allow ZBH to continue selling an exclusive version of THINK’s wireless, handheld TMINI Miniature Robotic System, which is compatible with ZBH’s Persona Knee System. The deal follows a successful initial term and is intended to accelerate adoption of the TMINI system among ZBH’s customers and patients. The partnership underscores the perceived value of the robotic technology and reinforces ZBH’s position in the orthopedic robotics market.
What did this article say?
Zimmer Biomet Holdings announced a multi‑year extension of its distribution and supply agreement with THINK Surgical to continue marketing THINK’s Wireless TMINI miniature robotic system. The deal expands ZBH’s presence in the orthopedic robotics market and secures a steady revenue stream from a growing product line. The partnership reinforces ZBH’s strategy to broaden its surgical technology portfolio and capture additional market share in minimally invasive procedures.
What did this article say?
The article reviews the Q2 earnings season for the surgical equipment and consumables industry, highlighting Zimmer Biomet (NYSE:ZBH) among its peers. It outlines the sector’s stable demand driven by medical interventions, recurring consumable revenue, and long‑term hospital contracts. The piece also notes industry challenges such as high R&D costs, regulatory compliance, and pricing pressure from cost‑conscious customers. It mentions potential tailwinds, including an aging population and the integration of AI and robotics into surgical procedures. No specific financial metrics or performance details for ZBH are provided, leaving the assessment neutral.
What did this article say?
Leerink Partners lowered its price target for Zimmer Biomet (ZBH) to $97 from $106, reflecting a downgrade in the analyst’s outlook. The firm cited concerns over the company’s earnings outlook and competitive pressures in the orthopedic market. The adjustment signals a modest negative view on ZBH’s near‑term valuation, though the company remains a hold rating. This change may influence investor sentiment and trading activity around the stock.
What did this article say?
Evercore ISI increased its price target for Zimmer Biomet Holdings (ZBH) to $115 from $110, reflecting a more optimistic view of the company’s prospects. The rating remains a hold, but the higher target suggests confidence in ZBH’s ability to generate stronger earnings. The adjustment aligns with analysts’ expectations of continued growth in the medical device sector and improved margin dynamics.
What did this article say?
Barclays analyst Christopher Pasquale announced the initiation of coverage on Zimmer Biomet Holdings (NYSE:ZBH), assigning an Equal‑Weight rating. The bank set a price target of $100 for the stock. The move signals a neutral stance, indicating no immediate upside or downside expectation beyond the baseline valuation. The coverage does not suggest any immediate material change in the company’s outlook.
What did this article say?
Zimmer Biomet Holdings announced that its third‑quarter 2026 earnings conference call would be webcast on November 4, 2026, at 8:30 a.m. ET. A news release detailing the quarterly results was to be made available that day at 6:30 a.m. ET. The company provided dial‑in numbers for U.S., Canada, and international participants and noted that the webcast would be replayed after the call.
What did this article say?
Zimmer Biomet (ZBH) reported modest performance, trading at $91.50 with a 4.4% compounded annual sales growth over five years, below sector expectations. Earnings per share growth was also limited, prompting analysts to view the stock as less attractive compared to peers. The company’s return lagged the S&P 500’s 16.9% gain during the same period, reinforcing concerns about upside potential. Analysts recommend exploring alternative opportunities rather than adding ZBH to portfolios. The commentary reflects a cautious stance on the company’s current trajectory.
What did this article say?
Zimmer Biomet Holdings (ZBH) reported a modest 1.3% decline in its share price on September 25, with a 10.5% drop over the preceding month, reflecting a cooling in investor sentiment. The company’s cost reset strategy, aimed at shifting R&D activities to a global capability center, was highlighted as a key driver of recent performance. Despite the share price pressure, ZBH remains approximately 17% below its fair value estimate, suggesting potential upside if the cost initiatives materialize. The market’s reaction indicates that while the company’s fundamentals are solid, the immediate impact of the cost reset plans is viewed as a mild headwind rather than a transformative shift.

Technical Analysis

Real-time indicators across multiple timeframes

31
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $6.80B combined position · 14 adding, 11 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy23,483,74112.12%$2.11B2026-01-29
BlackRock, Inc.▲ Buy15,614,8478.06%$1.34B2026-08-07
Harris Associates L P▼ Sell12,738,0256.57%$1.10B2026-08-14
Geode Capital Management, LLC▼ Sell5,349,2232.76%$458.75M2026-08-12
Invesco Ltd.▲ Buy3,979,8602.05%$342.63M2026-08-14
Citadel Advisors LLC▲ Buy3,477,4721.79%$299.38M2026-09-02
Morgan Stanley▲ Buy2,591,5031.34%$223.10M2026-08-13
Bank of America Corp▲ Buy2,177,7241.12%$187.48M2026-08-14
Northern Trust Corp▼ Sell1,965,0521.01%$169.17M2026-08-13
Norges Bank▼ Sell1,587,4310.82%$136.66M2026-08-12
Goldman Sachs Group Inc▼ Sell968,6280.50%$83.39M2026-08-14
Point72 Asset Management, L.P.▲ Buy879,8510.45%$75.75M2026-08-14
JPMorgan Chase & Co▼ Sell815,9140.42%$74.44M2026-08-12
AQR Capital Management LLC▲ Buy367,3650.19%$31.29M2026-08-14
Citigroup Inc▲ Buy258,9820.13%$22.30M2026-08-03
AllianceBernstein L.P.▼ Sell214,9370.11%$19.43M2026-08-14
Millennium Management LLC▼ Sell222,0650.11%$19.12M2026-08-14
Moore Capital Management, LP▲ Buy198,6420.10%$17.10M2026-08-14
ExodusPoint Capital Management, LP▲ Buy180,8840.09%$15.57M2026-08-14
Wells Fargo & Company▼ Sell178,5910.09%$15.37M2026-08-14
Schonfeld Strategic Advisors LLC▲ Buy603,2160.31%$12.73M2026-08-14
Marshall Wace, LLP▲ Buy144,5000.07%$12.44M2026-08-13
Neuberger Berman Group LLC▼ Sell129,5730.07%$11.15M2026-08-13
Adage Capital Partners GP, L.L.C.▲ Buy96,9420.05%$8.35M2026-08-14
Prudential Financial Inc▼ Sell91,7560.05%$7.90M2026-08-12
Q2 2026 flow:5.33M sh bought ($449.83M)1.38M sh sold ($118.52M)net +3.96M sh (+$331.31M)
Congressional Trading Activity
6 disclosed trades · ~$48.0K est. traded value · 2 buys, 4 sells
MemberChamberStateTypeAmountTradedFiled
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-05-152025-05-31
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-04-082025-05-08
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-02-112025-03-12
John F. ReedSenateRI▼ Sell$1K - $15K2016-12-162017-01-04
John F. ReedSenateRI▼ Sell$1K - $15K2016-07-252016-07-27